



Signalife

Clear Data. Trusted Results.

Signalife, Inc.
531 South Main St. ~ Suite 301
Greenville, SC 29601
T 864.233.2300
F 864.233.2100
www.signalife.com
info@signalife.com

PRESS RELEASE

Monday January 30, 2006 | 2:28 pm ET

Signalife Successfully Completes DIVA Study at Duke University

GREENVILLE, S.C.--(BUSINESS WIRE)--Jan. 30, 2006--Signalife, Inc (AMEX: SGN - News) today announced that Duke University has completed the Device Implementation, Validation and Application (DIVA) Program for the company's initial product, the Fidelity 100 Ambulatory EKG/ECG Monitor. A total of 108 patients, with clinical indications for elective or possible percutaneous coronary intervention (PCI), were recorded at the Catheterization Laboratory at the Durham, VA, Medical Center to provide detailed documentation of the device's ability to detect and quantify transient ischemic episodes in comparison to conventional ECG devices.

Data is currently being analyzed by the eECG Core Laboratory at the Duke Clinical Research Institute (DCRI). Dr. Mitchell W. Krucoff, M.D., Principal Investigator of the DIVA study, states: "We are excited to have finished the data collection and look forward to the imminent completion of data analysis so that we can unblind and report the results. From the preliminary waveform scanning, we are very pleased with the quality of the ECG recordings obtained for the Signalife DIVA."

Dr. Budimir S. Drakulic, Chief Technology Officer of Signalife, states: "Since the inception of Signalife, we have made a major investment in the development and clinical validation of our technology. We are very excited about our current and future collaborations with two of the leading cardiac centers in the U.S., Duke University and Cleveland Clinic Foundation."

Pamela Bunes, President and CEO of Signalife, said: "The successful completion of the Duke University DIVA study is a significant milestone for the company. The DIVA study, along with new clinical studies that we plan to initiate at the Cleveland Clinic, will definitely demonstrate that previously un-captured data about the heart will now be available for use by the entire cardiology community. We are confident that revolutionary state-of-the-art products will allow for improved patient monitoring before, during, and following cardiac procedures."

About Signalife, Inc.

Signalife, Inc. is a medical device company focused on the detection of cardiovascular disease through continuous ECG signal monitoring. The company's goal is to become the premier global provider of disease monitoring products. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory environment. Signalife's revolutionary FDA-approved patented electrocardiograph (ECG) monitoring system called Fidelity 100 allows for the recording of a high-quality ECG signal from cardiac patients who are moving. This means for the first time physicians will have immediate access to clinical real-time vital heart information. The Fidelity 100 will address the \$400 billion cardiac disease market which continues to grow rapidly. Signalife, Inc. is traded on the American Stock Exchange under the symbol SGN. More information is located at <http://www.signalife.com>.

Contact:

Signalife, Inc.
Corporate Communications:
Claire Mouton LaFrance, 864-233-2300
clafrance@signalife.com

or

Duke University Medical Center
Dr. Mitchell W. Krucoff, 919-286-6860

or

Media:

5W Public Relations
Adam J. Handelsman, 212-999-5585, ext. 202
ahandelsman@5wpr.com

or

Investor Relations:

Mark Cohen, 212-999-5585
mcohen@5wpr.com

Caution Regarding Forward-Looking Statements

Statements in this release □
which may cause Signalife's actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences
include, but are not limited □
tory approvals governing medica □
Signalife's products o □
to complete management's plans and objectives. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further
described in Signalife's filings with the Securities and Exchange Commission nancing

###